Feb 13 2020

Official Website – Innovation today, healthier tomorrows: Sunovion Pharmaceuticals Europe Ltd, sunovion pharmaceuticals.

#Sunovion #pharmaceuticals

Sunovion pharmaceuticals

Sunovion pharmaceuticals

  • Sunovion pharmaceuticals
  • Sunovion pharmaceuticals
    • Small
    • Normal
    • Large

Sunovion pharmaceuticals

Sunovion Europe specialises in improving people’s health and wellbeing:

At Sunovion Pharmaceuticals Europe Ltd. (Sunovion Europe) we focus on the development and introduction of innovative medicines that improve people’s health and wellbeing. We currently specialise in Psychiatry and Neurology – including mental health – and other areas of unmet medical need that require highly specialised drug development. For more information click here.

About Sunovion Pharmaceuticals Europe Ltd.

Sunovion Pharmaceuticals Europe, headquartered in London, United Kingdom, is a wholly-owned direct subsidiary of Sunovion Pharmaceuticals Inc.. Sunovion Pharmaceuticals Europe defines its corporate mission as to broadly contribute to society through value creation based on innovative research and development activities for the betterment of healthcare and fuller lives for people worldwide . We work together with our colleagues globally to develop and introduce innovative medicines in Europe.

Sunovion Pharmaceuticals Inc., an indirect, wholly-owned subsidiary of Sumitomo Dainippon Pharma, is headquartered in Marlborough, Mass. Sunovion is a leading pharmaceutical company dedicated to discovering, developing and commercializing therapeutic products that advance the science of medicine and improve the lives of patients and their families.

About Sumitomo Dainippon Pharma Co., Ltd.

Sumitomo Dainippon Pharma is a multi-billion dollar, top-ten listed pharmaceutical company in Japan. A growing R D product pipeline and portfolio represent a significant step in positioning Sumitomo Dainippon Pharma as an internationally recognised global pharmaceutical company. Sumitomo Dainippon Pharma aims to produce innovative pharmaceutical products encompassing two key therapeutic areas (1) Psychiatry and Neurology and (2) Oncology. Sumitomo Dainippon Pharma is based on the merger in 2005 between Dainippon Pharmaceutical Co., Ltd., and Sumitomo Pharmaceuticals Co., Ltd. Today, Sumitomo Dainippon Pharma has more than 7,000 employees worldwide. Additional information about Sumitomo Dainippon Pharma is available through its corporate website at

Sunovion pharmaceuticals

Written by admin